


PF-04634817 succinate

Chemical Properties

CAS No. : 2140301-98-8
 Formula: C₂₉H₄₂F₃N₅O₇
 Molecular Weight: 629.67
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
 Actual storage temperature shall be subject to the COA.



Biological Description

Description	PF-0463481 succinate is a potent and orally active dual antagonist of CCR2/CCR5, exhibiting comparable human and rodent CCR2 potency with an IC ₅₀ of 20.8 nM.
Targets(IC ₅₀)	CCR,COX
In vivo	Early intervention with PF-04634817 induces an additional increase in glycated hemoglobin (HbA1c) levels[1].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.5881 mL	7.9407 mL	15.8813 mL
5 mM	0.3176 mL	1.5881 mL	3.1763 mL
10 mM	0.1588 mL	0.7941 mL	1.5881 mL
50 mM	0.0318 mL	0.1588 mL	0.3176 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Tesch GH, et al. Combined inhibition of CCR2 and ACE provides added protection against progression of diabetic nephropathy in Nos3-deficient mice. *Am J Physiol Renal Physiol*. 2019 Dec 1;317(6):F1439-F1449.

Gale JD, et al. A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema. *Invest Ophthalmol Vis Sci*. 2018 May 1;59(6):2659-2669.

Gale JD, et al. Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy. *Kidney Int Rep*. 2018 Aug 3;3(6):1316-1327.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481